Cyclacel Pharmaceuticals (BGMS) Stock Price, News & Analysis

Company Overview

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company's research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules. One of the company’s best-known programs is fadraciclib (also known as CYC065), a cyclin-dependent kinase inhibitor that has been investigated in clinical studies for multiple cancer indications. Beyond individual assets, Cyclacel’s pipeline reflects a strategy of pursuing mechanistically driven compounds that can be combined with standard-of-care therapies or other targeted agents to improve clinical outcomes.

Cyclacel conducts clinical development activities and collaborates with research institutions and potential industry partners to support its programs and expand clinical testing across multiple jurisdictions. As a publicly traded company, Cyclacel engages with the investor and scientific communities to communicate progress on its development milestones. Management and scientific leadership are focused on progressing late-stage preclinical work and clinical studies while exploring partnerships to advance commercialization pathways for its therapeutics.

Key Stats

• Today's Range: $0.92 to $0.95
• 50-Day Range: $0.60 to $1.50
• 52-Week Range: $0.57 to $9.53
• Volume: 2,831 shs
• Average Volume: 1.01 million shs
• Market Capitalization: $5.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

Cyclacel Pharmaceuticals scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Cyclacel Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Cyclacel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyclacel Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cyclacel Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cyclacel Pharmaceuticals has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.41% of the float of Cyclacel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 1.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclacel Pharmaceuticals has recently decreased by 0.77%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclacel Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.75% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Industrials
• Industry: Trading Companies & Distributors
• Sub-Industry: Trading Companies & Distributors
• Current Symbol: NASDAQ:BGMS
• CIK: 1130166
• Web: N/A
• Phone: (908) 517-7330
• Fax: 866-271-3466
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3 million
• Net Margins: N/A
• Pretax Margin: 68.72%
• Return on Equity: -51.21%
• Return on Assets: -44.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.06
• Quick Ratio: 5.87

Sales & Book Value

• Annual Sales: $750 thousand
• Price / Sales: 6.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.40 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 5,520,000
• Free Float: 4,208,000
• Market Cap: $5.02 million
• Optionable: N/A
• Beta: -0.38